Pharmaceuticals Buyers & Acquisitions in Georgia

Tracked deals

5

5 tracked deals across 2020-2024.

Buyer mix

Strategic-led

4 strategic · 2 pe

Top trend

Volume peaked in 2021

2 tracked deals announced in 2021.

Buyer Snapshot

Top Buyers

Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.

Build a buyer list for your Pharmaceuticals deal →
Buyer # Deals Focus Type
ANI Pharmaceuticals, Inc. 1 Biopharmaceutical company developing, manufacturing, and ... Strategic
Advantage Capital 1 Impact investment firm providing growth and financing to ... PE
Amneal Pharmaceuticals, Inc. 1 Fully integrated pharmaceuticals company focused on gener... Strategic
Azurity Pharmaceuticals, Inc. 1 Privately-held specialty pharmaceutical company focused o... Strategic (PE-backed)
Neogen Corporation 1 Developer and marketer of food and animal safety products... Strategic
NovaQuest Private Equity 1 Life-sciences and healthcare-focused private equity inves... PE

Acquisition Volume in Pharmaceuticals in Georgia by Year

Last 4 years

Acquisition volume by year Annual acquisition counts for the last 4 years for Pharmaceuticals Buyers & Acquisitions in Georgia. 1 2020 2 2021 1 2022 1 2024

Supporting Data

Recent Transactions

  • ANI Pharmaceuticals Fights Alimera Sciences Lawsuit to Compel Closing of Merger
    September 10, 2024
    Buyer
    ANI Pharmaceuticals, Inc.
    Target
    Alimera Sciences, Inc.
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Buyout

    Alimera Sciences filed a lawsuit in Delaware Court of Chancery seeking to compel ANI Pharmaceuticals to close their previously announced merger under the June 21, 2024 Agreement and Plan of Merger. Alimera says it satisfied its own closing requirements and that its shareholders approved the transaction on September 4, 2024, while ANI allegedly failed to close on time.

  • Amneal Acquires Saol Therapeutics' Baclofen Franchise
    January 5, 2022
    Buyer
    Amneal Pharmaceuticals, Inc.
    Target
    Saol Therapeutics' Baclofen franchise
    Seller
    Saol Therapeutics
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Divestiture

    Amneal Pharmaceuticals has agreed to acquire Saol Therapeutics' Baclofen franchise, including Lioresal and LYVISPAHTM, for approximately $83.5 million in cash plus certain low double-digit royalties. The deal expands Amneal's neurology and specialty portfolio, adds institutional commercial infrastructure ahead of its planned biosimilars launches, and is expected to be accretive to Amneal's 2022 adjusted EBITDA and EPS.

  • Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals
    September 24, 2021
    Buyer
    Azurity Pharmaceuticals, Inc., NovaQuest Private Equity
    Target
    Arbor Pharmaceuticals, Inc.
    Seller
    JW Asset Management, KKR
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Addon

    Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

  • Neogen Acquires CAPInnoVet, Inc.
    September 20, 2021
    Buyer
    Neogen Corporation
    Target
    CAPInnoVet, Inc.
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Buyout

    Neogen Corporation has acquired Atlanta-based CAPInnoVet, Inc., a companion animal health company that provides pet medications to the veterinary market. The acquisition gives Neogen entry into the retail parasiticide market and will integrate CAPInnoVet into Neogen's Animal Safety business segment; terms were not disclosed.

  • Advantage Capital Makes $2M Growth Investment in GAXtracts
    June 8, 2020
    Buyer
    Advantage Capital
    Target
    GAXtracts
    Industry
    Pharmaceuticals
    Location
    Georgia, United States
    Type
    Growth capital

    Advantage Capital invested $2 million in Watkinsville-based GAXtracts to provide working capital and equipment financing under Georgia’s GARJA program. The growth capital will support facility expansion, the purchase of new equipment and is expected to create 30 new local jobs as GAXtracts scales production of hemp-derived active pharmaceutical ingredients and CBD products.

Build a buyer list for your Pharmaceuticals deal

Find buyers actively acquiring pharmaceuticals companies.

Apply as a Buyer

Related Acquisition Pages

Pharmaceuticals Buyers & Acquisitions Pharmaceuticals Buyers & Acquisitions in Canada Private Equity-Backed Pharmaceuticals Buyers Pharmaceuticals Acquisitions in 2024 Pharmaceuticals Acquisitions in 2022 Pharmaceuticals Acquisitions in 2021 Pharmaceuticals Acquisitions in 2020 Acquisitions in Georgia Private Equity-Backed Acquisitions in Georgia Acquisitions in Georgia in 2024 Acquisitions in Georgia in 2022 Acquisitions in Georgia in 2021